Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + zimberelimab + chemotherapy versus pembrolizumab + chemotherapy in untreated metastatic non-small cell lung cancer
NL-OMON60907Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Domvanalimab + zimberelimab + chemotherapy with Pembrolizumab + chemotherapy (2 arms). Primary endpoints: Overall survival in PD-L1-positive participants and Overall survival in all randomized participants. Started May 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60907.